BIO-key has been approved for Nasdaq listing.
It’s the realization of a longstanding ambition on the company’s part, and comes soon after BIO-key took preparatory measures including the establishment of a major, long-term stock purchase agreement and the appointment of a new Audit Committee Chair to its Board of Directors. It also comes after the company reported a strong uptick in sales to the healthcare sector in Q2.
In a statement announcing the Nasdaq approval, BIO-key CEO Mike DePasquale called it “a significant milestone for BIO-key and our shareholders, that underscores our ramping sales momentum so far this year.”
“In addition to providing a range of benefits to our shareholders, we believe listing on Nasdaq will also support our sales and marketing momentum by raising the visibility of our brand and authentication solutions before prospective customers, partners and the media,” said DePasquale.
The Nasdaq will list BIO-key starting Tuesday, July 25th.
–Follow this link to learn more about the BIO-key’s new consumer biometrics concept: The Biometric of Things–
July 21, 2017 – by Alex Perala